The prevalence of diabetes in North America is estimated to be 12.9% ([@B1]), and, of these patients, 50% develop diabetic peripheral neuropathy (DPN) ([@B2]). Up to 25% of patients with DPN develop neuropathic pain ([@B3]), defined as "pain arising as a direct consequence of a lesion or disease affecting the somatosensory system" ([@B4]). Common descriptors include burning pain, "electrical shock" or shooting pain down the legs, and pain on contact with socks or bedclothes at night (allodynia). The pain is characteristically more severe at night and often disturbs sleep. Painful diabetic peripheral neuropathy (PDPN) can have a major impact on physical and mental functioning, thereby compromising the ability to work, attend to household responsibilities, and enjoy social relationships.

Findings from trials of PDPN treatments inform the management of other neuropathic pain conditions. Current evidence indicates that pharmacotherapy for neuropathic pain provides only partial pain relief, is not well tolerated (and therefore cannot be used) by many patients, and is associated with effects that can adversely affect patient safety and quality of life (QoL) ([@B5],[@B6]). This is especially true with opiates, which are no longer recommended. Both the National Institute for Health and Care Excellence ([@B7]) and the American Diabetes Association's *Standards of Medical Care in Diabetes---2017* ([@B8]) endorse the essential role of psychosocial therapies in restoring physical and emotional functioning in patients with diabetes.

Mindfulness-based stress reduction (MBSR) is a group psychosocial intervention that was first developed by Kabat-Zinn ([@B9]) for patients with chronic illness who were not responding to existing medical treatments. Through mindfulness exercises, participants develop the ability to take the position of a witness to their experiences (meta-cognition), allowing a more objective assessment of stressors (such as pain) and improved self-regulation. This facilitates the choice of more adaptive responses rather than catastrophic ruminations or automatic reactions. The threat and sense of harm associated with pain, and even its intensity, can be diminished by developing a more open and accepting attitude toward this challenging experience.

The possibility of using mental training to change how pain is processed in the central nervous system and thereby diminish the pain experience is supported by recent research in neuroscience ([@B10]). Although MBSR has shown promise for a variety of painful conditions, there are few methodologically robust studies, and we have found no studies of cohorts with neuropathic pain.

The primary objective of this randomized, controlled trial was to evaluate the effectiveness of community-based MBSR courses to improve physical and mental functioning among patients with PDPN whose medical treatment has been optimized. Secondary objectives were to evaluate the effect of the intervention on pain severity, mood, and health-related QoL, as well as on diabetes self-care activities and glycemic control.

Research Design and Methods {#s1}
===========================

Participants {#s2}
------------

With approval from the Ottawa Health Sciences Network ethics board and after obtaining informed written consent, we enrolled patients in this wait list--controlled, randomized trial between 5 July 2013 and 4 September 2015. The trial was registered with [ClincalTrials.gov](http://ClincalTrials.gov) (NCT 02127762).

Most patients were recruited by telephone from a database of patients attending The Ottawa Hospital's Endocrine and Diabetes Centre who had consented to be contacted regarding research participation. Others were referred from the community. Men and women who were ≥18 years of age, had type 1 or type 2 diabetes and symptoms of PDPN for \>6 months, and could speak English or French and understand and complete our questionnaires were eligible to participate. Patients responding "yes" to ≥3 of the 7 subjective items on the Douleur Neuropathique 4 (DN4) ([@B11]) neuropathic pain scale were then asked to rate their pain on two visual analog scales rating from 0 to 10 their pain at rest and with activity) at the same time of day for 7 consecutive days. Patients were included if their mean score for either scale was ≥4. Patients were excluded if they had previously taken an MBSR or similar course.

Methods
-------

At the first visit, patients were examined by a pain specialist who completed the DN4 and the clinical examination portion of the Michigan Neuropathy Screening Instrument ([@B12]) to confirm and document the severity of their neuropathy. All patients were given an explanation of the neurobiology of chronic pain and of how MBSR might improve their mental and physical functioning. Pharmacological treatment, usually pregabalin and duloxetine or a tricyclic antidepressant, was offered ([@B5]). Up to 5 months were allowed for optimization and stabilization of medication.

### Randomization and Blinding {#s3}

Patients were randomly allocated to a waiting list or MBSR using computer-generated random numbers in a permuted block design with randomly varying block lengths. Allocations were stratified by type 1 or type 2 diabetes and by pain severity as indicated by an average of the four pain-severity numeric rating scales of the Brief Pain Inventory (BPI; questions 3--6) ([@B13]) rated daily for the 7 days immediately before randomization. Ratings of 4--6 were classified as moderate pain and ratings of 7--10 as severe pain. Baseline pain intensity is known to be an important prognostic variable ([@B14]). Allocations were generated by an independent statistician and concealed from investigators and treating physicians. Treatment allocation occurred as close as possible to the start of the MBSR course when the next consecutively numbered opaque envelope for the appropriate strata was opened. After randomization, participants had had sufficient experience with the instruments that they were able to complete them without any contact from study staff who were aware of the treatment allocation.

### Intervention {#s4}

Patients were enrolled in MBSR courses offered at multiple sites in the community by practitioners who had formal training in MBSR and ≥5 years of experience as workshop leaders. The methods and materials described in the teacher training course given by the Center for Mindfulness at the University of Massachusetts, where this method was developed, were used ([@B15]). The workshops consisted on nine sessions: eight weekly, 2.5-hour sessions and one 6-hour session on a weekend day midway through the course. Typically, 2--3 study patients would join a group of 12--20 MBSR participants with a variety of complaints such as pain, anxiety, or depression. There was no modification of the MBSR course for the purposes of this study. Patients in both the control and MBSR groups were discouraged from making any changes in medication from the time of randomization until after the final assessment. Patients in the control group were offered enrollment in an MBSR course after the study was complete.

### Measures {#s6}

Socio-demographic measures were collected at baseline. All outcomes were measured at baseline (visit 1, denoted as V1) when pharmacological treatment was offered, at the time of randomization (visit 2, denoted as V2), and at 2 weeks (visit 3, denoted as V3) and 3 months (visit 4, denoted as V4) after completion of the MBSR course. Control subjects had the same measures at the same intervals. A1C was measured at V1, V2, and V4.

Primary Outcome {#s7}
---------------

Our primary outcome was a comparison of the prevalence in each group of response to the intervention, defined as a decrease of ≥1.0 on the mean of the seven interference scale items of the BPI (completed daily for 7 days) from the time of randomization (V2) to the 3-month follow-up (V4). The BPI is a measure of pain-related disability that is both recommended by the Initiative on Methods, Measurement, and Pain Assessment in Clinical Trials (IMMPACT) guidelines ([@B16],[@B17]) and has been found by Jensen et al. ([@B18]) to be more sensitive to neuropathic pain than generic measures of health-related QoL. Zelman et al. ([@B13]) has validated the BPI for PDPN. The IMMPACT guidelines recommend a one-point change on the interference scale as a reasonable minimally clinically important change ([@B16]). The primary hypothesis was that participants in the study's MBSR arm would have a 30% absolute greater prevalence of response than those in the control arm 3 months after completion of MBSR.

Secondary Outcomes {#s8}
------------------

Secondary outcomes included:IMMPACT-recommended measures ([@B16],[@B17]), including the BPI for pain severity, the Patient Health Questionnaire-9 (PHQ-9) ([@B19]) for depression, the Patient Global Impression of Change (PGIC) ([@B20]) for QoL, the Profile of Mood States-2A (POMS-2A) for total mood disturbance (reported here), and the Perceived Stress Scale (PSS) ([@B21]), as well as adverse events records.The Pain Catastrophizing Scale (PCS) ([@B22]), a well-validated 13-item instrument designed to evaluate the degree to which patients have negative self-statements and catastrophizing thoughts and ideations when in pain.Short Form-12 Health Survey ver-sion 2 (SF-12) ([@B23]), a brief, 12-item generic measure of QoL. The SF-12 has been used in studies of back pain ([@B24]) and neuropathic pain ([@B25]). It includes eight subdomains: bodily pain, physical functioning, role physical, general health, vitality, social functioning, role emotional, and mental health. Two composite scores are calculated: Physical and Mental Health Composite Scales.Neuropathy-Specific Quality of Life Questionnaire (NeuroQoL) ([@B26]), which was designed for and validated in patients with DPN and captures the key dimensions of patients' experience. Factor analysis revealed three physical symptom measures and two psychosocial functioning measures with good reliability (α = 0.86--0.95). This instrument was more strongly associated with severity of DPN than the SF-12 and more fully mediated the relationship between DPN and overall QoL.

In addition, to address our interest in the possible benefits of MBSR on glycemic control, we included the following:Summary of Diabetes Self-Care Activities ([@B27]), an 11-item self-report measure used to assess the diet, exercise, smoking, self-monitoring of blood glucose, and foot care habits of patients with diabetes. This scale has been found to be valid with moderate test-retest reliability.Blood Sugar Reactions Question-naire. To assess adverse reactions patients may have experienced as a result of their glycemic control, we have used five questions from the Diabetes Care Profile of the Michigan Diabetes Research and Training Center (Section 6, questions 1--3, 5, and 6) ([@B28]).A1C, which reflects blood glucose levels during the previous 12 weeks.

Sample Size {#s10}
-----------

The sample size was determined to achieve 80% power to detect a minimally important absolute difference of 30% in the percentage of responders 3 months after intervention, assuming a control-arm percentage of 20%, an average of two study participants per MBSR group, an intracluster correlation coefficient (ICC) of 0.05, and a two-sided test at the 5% level of significance ([@B29]). The ICC accounts for the lack of statistical independence among responses from participants in the same therapy group; failing to account for the ICC risks underestimating the required sample size. We had no prior information regarding the ICC and therefore assumed a value of 0.05, which is commonly assumed in cluster-randomized trials ([@B30]). We chose a minimum detectable difference of 30% because that is the smallest difference that would encourage us to recommend this intervention. Based on these assumptions, we required a total of 80 patients. However, the study was stopped after 66 patients had been randomized due to exhaustion of funds.

Statistical Analysis {#s11}
--------------------

The primary outcome at 3 months (proportion of responders on the BPI) was analyzed using mixed-effects logistic regression accounting for the partially nested design and using random effects for therapy group. Degrees of freedom were calculated using the Kenward-Roger method. The analysis accounted for the stratification variables as fixed effects; it also adjusted for continuous BPI score at the time of randomization. The results of the binary outcomes were expressed as odds ratios (ORs) with 95% CIs rather than as an absolute risk difference because the binomial identity model did not converge, and we were therefore unable to calculate CIs around the absolute risk difference that appropriately accounted for clustering by therapy group. The ICC for the primary outcome was estimated using variance components from a one-way analysis of variance together with a 95% exact CI ([@B31]). The patient global impression of change was analyzed as a binary variable. Patients who reported "much improvement" or "very much improvement" at the 12-week follow-up were considered responders ([@B20]).

Continuous secondary outcomes measured at the time of randomization and 2 weeks and 3 months after the intervention were analyzed using mixed-effects linear regression, accounting for the partially nested design and allowing for a heterogeneous variance structure ([@B32]). To take into account the partially nested design, a term accounting for variability between treatment clusters was added to the variance of the effect of treatment. This increased the standard error of the mean in the intervention arm, providing valid inferences about the effect of treatment. Had the clustering in the treatment arm not been taken into account, the resulting CIs would have been too narrow and *P* values would have been too small. Degrees of freedom were calculated using the Kenward-Roger method. The analysis accounted for the correlation in repeated measures on the same subject over time using a compound symmetric covariance structure.

Differences between the study arms over time were assessed by including visit (analyzed as a categorical variable), treatment arm, and the interaction between visit and treatment arm in the models. Analyses accounted for the stratification variables as fixed effects. To improve precision of the treatment effect estimator, our analysis also adjusted for prespecified baseline covariates anticipated to be strongly correlated with the response, namely the baseline measure of each outcome, education status, BPI interference score, and age in years. Least squares means were obtained from the model and used to calculate the mean change from the time of randomization to 2 weeks and 3 months after intervention in each group with 95% CIs. The effect of the intervention was expressed as between-arm least squares mean differences in change from baseline to 3 months with 95% CIs. All tests were evaluated at the two-sided 5% level of significance. SAS version 9.3 (SAS, Cary, N.C.) was used for all analyses.

Results {#s12}
=======

Two hundred and fifty-five subjects were screened for eligibility, of whom 66 were randomized. One hundred and eighty-nine were excluded for reasons shown in the CONSORT (Consolidated Standards of Reporting Trials) diagram ([Figure 1](#F1){ref-type="fig"}). Of the 33 subjects allocated to MBSR, 31 received the intervention and completed follow-up, and 30 were included in the analysis. One was excluded from the analysis when it was discovered that the eligibility requirement had not been met (screening visual analog scale \<4). Of the 33 patients allocated to the control group, one withdrew from the study, and 32 completed follow-up and analysis. Eighteen of the 30 subjects (60%) allocated to MBSR attended at least six of the nine sessions. There were 10 community groups, each attended by two to three study participants. No clinically important differences in patient characteristics at baseline were identified between the study arms ([Table 1](#T1){ref-type="table"}).

![CONSORT diagram of the study. VAS, visual analog scale.](294fig1){#F1}

###### 

Baseline Characteristics

                                         All (*n* = 62)   Control Group (*n* = 32)   MBSR Group (*n* = 30)
  -------------------------------------- ---------------- -------------------------- -----------------------
  Age (years; mean \[SD\])               59.7 (8.8)       59.8 (8.7)                 59.7 (9.1)
  Female (*n* \[%\])                     35 (56)          20 (62.5)                  15 (50)
  Type 2 diabetes (*n* \[%\])            48 (77)          24 (75)                    24 (80)
  Severe pain (*n* \[%\])                17 ([@B27])      8 ([@B25])                 9 ([@B30])
  Pain severity (mean \[SD\])            5.1 (1.8)        4.9 (2.0)                  5.3 (1.6)
  Pain interference (mean \[SD\])        4.8 (2.0)        4.8 (2.2)                  4.9 (1.8)
  Pain duration (years; mean \[SD\])     7.4 (6.0)        8.0 (6.7)                  6.7 (5.2)
  Post-secondary education (*n* \[%\])   46 (74)          23 (71.9)                  23 (76.7)
  Work status (*n* \[%\])                                                            
   Employed                              11(17.7)         4 (12.5)                   7 (23.3)
   Retired                               33 (53.2)        18 (56.3)                  15 (50)
   Disability                            15 (24.2)        8 ([@B25])                 7 (23.3)
   Other                                 3 (4.8)          2 (6.3)                    1 (3.3)
                                         **(*n* = 59)**   **(*n* = 31)**             **(*n* = 28)**
  A1C (% \[SD\])                         8.28 (1.37)      8.20 (1.37)                8.38 (1.40)
  A1C (mmol/mol \[SD\])                  67 ([@B15])      66 ([@B15])                68 (15.3)

Primary Outcome {#s13}
---------------

In the MBSR group, 19 of 30 patients (63.3%) experienced a decrease in the mean BPI interference score of ≥1.0 from the time of randomization (V2) to 12 weeks after completion of the MBSR course (V4) compared to 7 of 32 control patients (21.9%) during the same interval (adjusted OR 9.9, 95% CI 1.5--63.8, *P* = 0.02). The absolute difference of 41.4% (number needed to treat \[NNT\] 2.4) exceeded our minimally important clinical difference of 30%.

These findings are supported by the difference between groups in the PGIC score, with 14 of 30 in the MBSR group (46.7%) compared to 2 of 32 in the control group (6.2%) reporting that they were much or very much improved at the 12-week follow-up. The absolute difference was 40.5%, giving an NNT of 2.5 (adjusted OR 18.8, 95% CI 2.3--151.5, *P* = 0.007).

The estimated ICC for the primary outcome was 0.13 (95% CI --0.2 to 0.6).

Secondary Outcomes {#s14}
------------------

Adjusted mean scores at the time of randomization (V2), as well as adjusted mean change scores within groups and the between-group difference in change score between pre-randomization and the 12-week follow-up (V4 -- V2) are given in [Table 2](#T2){ref-type="table"}. For the SF-12 variables, an increase in score indicates a benefit of MBSR; for all other variables, a decrease in score (negative value for V4 -- V2) indicates a benefit or MBSR. Within the control group, measures either changed little or worsened over time. Within the MBSR group, all measures presented other than the SF-12 role emotion and A1C showed improvement 12 weeks after the course, with the 95% CI not including zero. There was also a general trend for progressive improvement between the 2- (V3) and 12-week (V4) follow-up visits ([Figure 2](#F2){ref-type="fig"}). Some of the improvements within the MBSR group at 12 weeks were unexpectedly large, with a 46.5% decrease in pain catastrophizing, a 42.0% decrease in the PHQ-9 (depression assessment), a 30.1% decrease in pain severity, and a 52.3% increase (improvement) in the SF-12 bodily pain subscale. Many of the between-group differences in change scores between pre-randomization and the 12-week follow-up (V4 -- V2, the prespecified comparison of interest) were statistically significant, showing a benefit of MBSR. Typically, the contrast did not reach significance when the 95% CI was wide or the control group showed some improvement.

###### 

Adjusted Mean Score at V2 (Pre-Randomization), Adjusted Mean Change Scores Within Groups, and Difference in Adjusted Mean Change Scores Between Groups

                                          Control Group (Mean \[95% CI\])   MBSR Group (Mean \[95% CI\])   MBSR (V4 -- V2) -- Control (V4 -- V2)   
  --------------------------------------- --------------------------------- ------------------------------ --------------------------------------- ---------
  BPI Interference                                                                                                                                 
   V2                                     4.65 (3.56--5.74)                 4.89 (4.08--5.69)                                                      
   V3 -- V2                               0.54 (--0.82 to 1.89)             --0.87 (--1.74 to 0.00)                                                
   V4 -- V2                               0.46 (--0.89 to 1.82)             --1.72 (--2.59 to --0.84)      --2.18 (--3.74 to --0.62)               0.006
  BPI Pain Severity                                                                                                                                
   V2                                     5.01 (4.50--5.52)                 5.27 (4.63--5.90)                                                      
   V3 -- V2                               0.55 (0.09--1.01)                 --1.05 (--1.74 to --0.36)                                              
   V4 -- V2                               0.33 (--0.12 to 0.78)             --1.59 (--2.29 to --0.90)      --1.92 (--2.74 to --1.10)               \<0.001
  Pain Catastrophizing                                                                                                                             
   V2                                     22.62 (19.15--26.09)              22.94 (19.23--26.64)                                                   
   V3 -- V2                               0.75 (--2.41 to 3.91)             --7.13 (--10.85 to --3.42)                                             
   V4 -- V2                               1.69 (--1.47 to 4.85)             --10.67 (--14.38 to --6.95)    --12.35 (--17.18 to --7.52)             \<0.001
  PHQ-9                                                                                                                                            
   V2                                     12.06 (10.44--13.68)              11.30 (9.65--12.95)                                                    
   V3 -- V2                               0.19 (--1.41 to 1.78)             --3.34 (--5.14 to --1.55)                                              
   V4 -- V2                               0.06 (--1.66 to 1.53)             --4.75 (--6.55 to --2.96)      --4.69 (--6.96 to --2.43)               \<0.001
  Perceived Stress                                                                                                                                 
   V2                                     19.76 (17.68--21.85)              19.20 (16.55--21.86)                                                   
   V3 -- V2                               0.50 (--1.39 to 2.39)             --2.83 (--6.09 to 0.42)                                                
   V4 -- V2                               1.75 (--0.14 to 3.64)             --4.64 (--7.89 to --1.38)      --6.39 (--10.06 to --2.71)              0.001
  SF-12 Mental Health Composite Scale                                                                                                              
   V2                                     43.45 (40.78--46.12)              43.20 (40.53--45.87)                                                   
   V3 -- V2                               --2.03 (--4.90 to 0.84)           2.98 (--0.09 to 5.87)                                                  
   V4 -- V2                               --1.88 (--4.75 to 0.98)           5.04 (2.18--7.90)              6.93 (2.92--10.93)                      \<0.001
  SF-12 Physical Health Composite Scale                                                                                                            
   V2                                     34.73 (31.91--37.55)              31.22 (27.85--34.60)                                                   
   V3 -- V2                               --0.03 (--3.36 to 3.30)           6.43 (3.12--9.74)                                                      
   V4 -- V2                               0.93 (--2.39 to 4.26)             5.82 (2.60--9.08)              4.89 (0.36--9.41)                       0.04
  SF-12 Bodily Pain                                                                                                                                
   V2                                     43.21 (34.05--52.37)              33.11 (22.79--43.43)                                                   
   V3 -- V2                               --3.13 (--12.16 to 5.91)          18.26 (6.12--30.41)                                                    
   V4 -- V2                               --2.34 (--11.37 to 6.69)          17.30 (5.35--29.25)            19.65 (5.05--34.24)                     0.01
  SF-12 Physical Function                                                                                                                          
   V2                                     30.35 (20.91--39.79)              22.98 (12.98--32.99)                                                   
   V3 -- V2                               --2.34 (--11.83 to 7.14)          17.55 (5.99--29.11)                                                    
   V4 -- V2                               0.78 (--8.70 to 10.27)            12.53 (0.97--24.09)            11.75 (--2.16 to 25.66)                 0.09
  SF-12 Role Physical                                                                                                                              
   V2                                     37.14 (27.27--47.02)              28.06 (17.43--38.70)                                                   
   V3 -- V2                               --2.34 (--10.53 to 5.84)          11.79 (1.11--22.46)                                                    
   V4 -- V2                               --2.73 (--10.92 to 5.45)          16.95 (6.28--27.63)            19.69 (6.58--32.80)                     0.004
  SF-12 General Health                                                                                                                             
   V2                                     31.86 (24.66--39.05)              27.85 (20.45--35.25)                                                   
   V3 -- V2                               0.16 (--6.93 to 7.24)             12.51 (5.71--19.31)                                                    
   V4 -- V2                               3.44 (--3.65 to 10.52)            16.17 (9.38--22.97)            12.74 (3.02--22.46)                     0.01
  SF-12 Vitality                                                                                                                                   
   V2                                     28.24 (20.94--35.54)              25.49 (17.13--33.84)                                                   
   V3 -- V2                               1.56 (--6.41 to 9.54)             15.17 (4.38--25.96)                                                    
   V4 -- V2                               7.03 (--0.94 to 15.01)            17.44 (6.79--28.10)            10.41 (--2.47 to 23.29)                 0.11
  SF-12 Social Function                                                                                                                            
   V2                                     52.48 (43.36--61.59)              39.93 (30.48--49.38)                                                   
   V3 -- V2                               --6.25 (--14.58 to 2.08)          18.00 (11.19--24.81)                                                   
   V4 -- V2                               --4.69 (--13.02 to 3.65)          20.83 (14.11--27.56)           25.52 (14.92--36.13)                    \<0.001
  SF-12 Role Emotion                                                                                                                               
   V2                                     56.76 (46.76--66.76)              58.21 (49.20--67.22)                                                   
   V3 -- V2                               --9.38 (--18.92 to 0.17)          6.04 (--3.11 to 15.19)                                                 
   V4 -- V2                               --5.47 (--15.01 to 4.08)          7.02 (--1.98 to 16.01)         12.49 (--0.28 to 25.26)                 0.06
  SF-12 Mental Health                                                                                                                              
   V2                                     54.97 (48.90--61.04)              54.18 (48.20--60.17)                                                   
   V3 -- V2                               --1.17 (--7.74 to 5.40)           5.71 (--0.96 to 12.39)                                                 
   V4 -- V2                               --5.47 (--12.04 to 1.10)          10.83 (4.23--17.44)            16.30 (7.08--25.52)                     \<0.001
  POMS2A -- tmd rs                                                                                                                                 
   V2                                     49.92 (41.43--58.40)              52.33 (39.31--65.34)                                                   
   V3 -- V2                               --4.66 (--12.58 to 3.27)          --17.04 (--34.65 to 0.58)                                              
   V4 -- V2                               --6.59 (--14.52 to 1.33)          --21.87 (--39.49 to --4.25)    --15.28 (--34.30 to 3.75)               0.11
  NQ Pain                                                                                                                                          
   V2                                     6.86 (5.57--8.16)                 6.39 (5.55--7.22)                                                      
   V3 -- V2                               0.54 (--0.89 to 1.98)             --1.22 (--0.45 to --2.00)                                              
   V4 -- V2                               0.90 (--0.53 to 2.33)             --1.39 (--2.16 to --0.61)      --2.28 (--3.90 to --0.66)               0.006
  NQ Feeling                                                                                                                                       
   V2                                     7.74 (6.33--9.14)                 7.72 (6.23--9.21)                                                      
   V3 -- V2                               1.00 (--0.48 to 2.48)             --1.26 (--2.47 to --0.06)                                              
   V4 -- V2                               --0.09 (--1.57 to 1.40)           --1.62 (--2.82 to --0.42)      --1.53 (--3.42 to --0.36)               0.11
  NQ Motor                                                                                                                                         
   V2                                     8.00 (6.64--9.38)                 8.01 (6.68--9.33)                                                      
   V3 -- V2                               --0.17 (--1.39 to 1.05)           --1.93 (--3.32 to --0.54)                                              
   V4 -- V2                               --0.86 (--2.08 to 0.36)           --2.16 (--3.55 to --0.77)      --1.30 (--3.12 to 0.51)                 0.16
  NQ Restrictions                                                                                                                                  
   V2                                     8.47 (7.10--9.84)                 8.80 (7.42--10.19)                                                     
   V3 -- V2                               --0.47 (--1.50 to 0.57)           --2.08 (--3.53 to --0.63)                                              
   V4 -- V2                               --0.44 (--1.47 to 0.60)           --2.25 (--3.70 to --0.80)      --1.81 (--3.55 to --0.07)               0.04
  NQ Disruptions                                                                                                                                   
   V2                                     7.11 (5.76--8.46)                 7.83 (6.52-- 9.13)                                                     
   V3 -- V2                               0.16 (--0.93 to 1.26)             --2.08 (--3.54 to --0.61)                                              
   V4 -- V2                               0.09 (--1.01 to 1.18)             --2.16 (--3.63 to --0.70)      --2.25 (--4.03 to --0.48)               0.01
  NQ Emotional                                                                                                                                     
   V2                                     7.41 (6.28--8.54)                 7.74 (6.53--8.95)                                                      
   V3 -- V2                               0.73 (--0.40 to 1.86)             --1.71 (--3.04 to --0.38)                                              
   V4 -- V2                               0.38 (--0.74 to 1.50)             --2.72 (--4.05 to --1.39)      --3.10 (--4.79 to --1.41)               \<0.001
  A1C (%)                                                                                                                                          
   V2                                     8.09 (7.78--8.41)                 8.58 (8.14--9.03)                                                      
   V3 -- V2                               0.16 (--0.68 to 0.99)             0.14 (--0.74 to 1.01)                                                  
   V4 -- V2                               0.07 (--0.14 to 0.27)             --0.31 (--0.80 to 0.19)        --0.37 (--0.90 to 0.57)                 0.16
  A1C (mmol/mol)                                                                                                                                   
   V2                                     65.0 (62.0--68.0)                 70.0 (65.0--75.0)                                                      
   V3 -- V2                               1.7 (--7.4 to 10.78)              1.5 (--8.1 to 11.0)                                                    
   V4 -- V2                               0.8 (--1.5 to 3.0)                --3.4 (--8.7 to 2.1)           --4.2 (-- 9.8 to 6.2)                   0.16

*Prespecified comparison of interest was between-group difference in change from V2 to V4 (column 4). For SF-12 variables, a higher score and a positive value in column 4 indicates benefit of MBSR. For all other variables, a lower score and a negative value in column 4 indicates benefit of MBSR*.

*BPI Interference, mean of the seven interference scales of the BPI; BPI Pain Severity, mean of the four pain severity scales of the BPI; Pain Catastrophizing, total score of the PCS; POMS2A -- tmd rs, POMS2A total mood disturbance raw score. NQ, NeuroQoL; NQ Pain, pain severity; NQ feeling, sensory changes; NQ motor, motor changes; NQ restrictions, interference with daily activities; NQ Disruptions, interference with emotional and physical roles; NQ Emotional, effect of neuropathy on mood*.

![Increasing improvements in pain interference, pain severity, pain catastrophizing, and depression from 2 to 12 weeks after MBSR. The numerals 2, 3, and 4 on the *x*-axis denote V2 (pre-randomization), V3 (2 weeks after the MBSR course), and V4 (12 weeks after the MBSR course). Bars indicate 1 SE.](294fig2){#F2}

A1C showed little change in either group. There were no significant between-group differences (V4 -- V2) on any subscales of the Summary of Diabetes Self-Care Activities or the blood glucose reactions questionnaire (not shown).

Discussion {#s15}
==========

Participation in an MBSR course improved function and reduced pain intensity, pain catastrophizing, depression, and perceived stress while improving health-related QoL. Many of these measures showed continued improvement from 2 to 12 weeks after the course ([Figure 2](#F2){ref-type="fig"}). Our experimental hypothesis, that the proportion of patients experiencing a decrease of ≥1 in mean BPI pain interference score would be ≥30% in the MBSR group, was confirmed (63.3 and 21.9% in the MBSR and control groups, respectively). The clinical meaningfulness of this finding is supported by the results of the PGIC scale, in which the proportion of patients endorsing much or very much improvement in their condition at the 12-week follow-up was 40.5% greater in the MBSR group than in the control group (46.7 vs. 6.2%). We did not demonstrate differences between groups in measures of diabetes self-care, blood glucose reactions, or A1C.

Our methods were guided by the IMMPACT recommendations ([@B16],[@B17]). This study is unique in selecting a homogeneous group of subjects all experiencing peripheral neuropathic pain, a feature that facilitates interpretation of the results. All patients were assessed by the principal investigator, and the diagnosis of PDPN was confirmed. At the first visit, each patient received a detailed explanation of the neurobiology of chronic pain and how MBSR might be beneficial. All patients had the opportunity to have drug treatment of their pain optimized during a period of up to 5 months before randomization. Our intention was that this would increase clinical relevance by demonstrating the added value of MBSR to best medical practice.

Multiple outcome domains were assessed to fully describe the clinical impact of treatment on patients' well-being. The primary outcome measure, BPI interference, as well as pain intensity, were assessed daily for 7 days at each visit to improve the reliability of self-reporting. The primary outcome (a decrease of ≥1 in mean BPI interference score) was recommended by IMMPACT because it correlates with patient perception of significant improvement (the PGIC).

Patient retention was excellent, with 94% of those randomized included in the analysis. A pragmatic aspect of the trial was the referral of subjects to community MBSR groups that included patients with differing symptoms. The intervention is therefore similar to the service available to patients in the community, in contrast to a specially designed modification of MBSR with groups consisting only of patients with PDPN.

We have found no published studies of a mindfulness intervention for a cohort of patients with chronic neuropathic pain. Cherkin et al. ([@B33]) recently reported the results of a large study comparing treatment as usual (TAU) to cognitive behavioral therapy (CBT) and MBSR for patients with low back pain, with follow-up of nearly 300 patients at 52 weeks after starting the intervention. Their primary outcomes were also binary, with clinically meaningful improvement defined as a 30% improvement from baseline on the modified Roland Disability Questionnaire (RDQ) or a back pain bothersomeness scale. At 26 weeks (14 weeks after course completion) in the MBSR group, 60.5% responded on the RDQ (vs. 44.1% in the TAU group); 43.6% responded on the bothersomeness scale (vs. 26.6% in the TAU group).

These response rates are similar to our study, although our control group showed less improvement, which may reflect a difference between the course of back pain compared to neuropathic pain, which is persistent. The magnitudes of change in their MBSR group at 26 weeks in measures of depression, pain intensity, and SF-12 Physical Health Composite Scale were similar to those found in the present study. We found significant improvement in the SF-12 Mental Health Composite Scale, whereas they did not.

Veehof et al. ([@B34]) published a meta-analysis of acceptance- and mindfulness-based interventions for the treatment of chronic pain, including 25 randomized, controlled trials with 1,285 patients. At follow-up (2--6 months after completing treatment), small effects (as measured with Cohen's standardized mean difference) were found on pain intensity (0.41) and disability (0.39); moderate effects on QoL (0.66), anxiety (0.59), and depression (0.3); and a large effect on pain interference (1.05). The authors observed that, as in the present study, effect sizes generally were larger several months after the intervention than during the first weeks after the course, suggesting long-term application of the course content rather than a nonspecific effect of the intervention.

In contrast, a Cochrane review by Williams et al. ([@B35]) of CBT for chronic pain found small post-treatment effects on pain intensity, mood, and disability that generally were not maintained at follow-up. Cherkin et al. ([@B33]), however, showed no such differences between CBT and MBSR for chronic back pain.

Both the pain subscale of the DPN-specific NeuroQoL and the BPI pain intensity scale, which interrogate about patients' experience of pain, showed reductions of 21.8 and 30.1%, respectively, 12 weeks after the MBSR course. It may seem surprising that a psychosocial intervention could result in a significant decrease in pain intensity, but this has been found in other studies ([@B36]). This finding supports the biopsychosocial model of pain ([@B37]), which postulates that the pain experienced by a patient depends on affective-motivational and cognitive-evaluative processes in the central nervous system and not only on the degree of nociceptor activation. Thus, MBSR may modulate the pain experience itself in addition to reducing the physical and emotional consequences of living with chronic pain.

van Son et al. ([@B38]) randomized patients with diabetes and emotional distress to a mindfulness course compared to a TAU group and found improvements in mood and health-related QoL similar to those found in the present study and likewise failed to demonstrate an effect on A1C. Meta-analyses of psychological interventions to improve glycemic control have yielded mixed results ([@B39]--[@B41]).

Strengths and Limitations {#s16}
-------------------------

There are few large trials of mindfulness-based interventions. In their meta-analysis of acceptance- and mindfulness-based interventions for the treatment of chronic pain, Veehof et al. ([@B34]) assigned quality points for an *n* ≥50 because that is deemed a sufficient number of participants to show standardized effect sizes ≥0.80, assuming statistical power of 0.80 and an alpha of 0.05. The consistency of our results across multiple domains affected by pain and the very low *P* values make it highly unlikely that the difference between the treatment and control groups occurred by chance.

The CI of some measures in our study are wide, and therefore the mean changes lack the precision that a future meta-analysis may provide. The choice of optimized treatment as usual care for the control group does not control for nonspecific effects and does not allow discovery of the mechanism of effect of the intervention. Subgroup analysis in Veehof et al.'s meta-analysis ([@B34]) comparing studies with TAU control groups to support group or education control groups showed a difference only for anxiety. Our priority was external validity with the intention to inform clinicians of the added value of referring their medically optimized patients with PDPN to a community MBSR course. As accumulating evidence establishes the efficacy of MBSR for neuropathic pain, attention may then be best directed to experiments with active control conditions that are designed to improve efficiency and efficacy by revealing the essential elements of the therapeutic effect ([@B42]).

Conclusion and Clinical Relevance {#s17}
=================================

Among patients with PDPN whose pharmacotherapy had been optimized in a chronic pain clinic, treatment with MBSR, compared with usual care, resulted in improved function; reduced pain intensity, pain catastrophizing, depression, and perceived stress; and better health-related QoL. Our results suggest that clinicians can expect their patients with PDPN to benefit from referral to community MBSR courses led by qualified teachers.
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